Literature DB >> 28544079

Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.

Jasmine Z Cheng1,2, Pearce G Wilcox1, Ian Glaspole3,4, Tamera J Corte5,6, Darra Murphy7, Cameron J Hague7, Christopher J Ryerson1,2.   

Abstract

BACKGROUND AND
OBJECTIVE: The objectives of this study were to determine the prevalence and characteristics of cough in idiopathic pulmonary fibrosis (IPF), chronic hypersensitivity pneumonitis (HP) and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
METHODS: Cough severity was measured in consecutive patients with IPF (n = 77), HP (n = 32) and SSc-ILD (n = 67) using a 10-cm visual analogue scale (VAS). Dyspnoea and quality of life were measured using established questionnaires. Cough severity was compared across ILD subtypes and predictors of cough severity were determined using multivariate analysis.
RESULTS: Cough was more common in IPF and chronic HP compared to SSc-ILD (87% and 83% vs 68%, P = 0.02). The median (interquartile range) VAS score was 39 (17-65) in the IPF cohort, 29 (11-48) in HP and 18 (0-33) in SSc-ILD (P < 0.0001). Cough was more often productive in chronic HP and IPF (63% and 43% vs 21%, P < 0.001). Cough severity was independently predicted only by ILD diagnosis and higher dyspnoea score. Cough severity was not associated with other common causes of cough. Cough was a significant predictor of quality of life in IPF and SSc-ILD with adjustment for age, sex, dyspnoea and ILD severity; however, cough was not associated with quality of life in chronic HP.
CONCLUSION: Cough is more frequent, more severe and more often productive in IPF and chronic HP compared to SSc-ILD, despite similar ILD severity in these cohorts. Cough severity is strongly and independently associated with dyspnoea and pulmonary function, and is a significant contributor to reduced quality of life in both IPF and SSc-ILD.
© 2017 Asian Pacific Society of Respirology.

Entities:  

Keywords:  cough; dyspnoea; hypersensitivity pneumonitis; idiopathic pulmonary fibrosis; systemic sclerosis

Mesh:

Year:  2017        PMID: 28544079     DOI: 10.1111/resp.13084

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  8 in total

Review 1.  Hypersensitivity pneumonitis.

Authors:  Ulrich Costabel; Yasunari Miyazaki; Annie Pardo; Dirk Koschel; Francesco Bonella; Paolo Spagnolo; Josune Guzman; Christopher J Ryerson; Moises Selman
Journal:  Nat Rev Dis Primers       Date:  2020-08-06       Impact factor: 52.329

Review 2.  Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease.

Authors:  Soumya Chatterjee; Apostolos Perelas; Ruchi Yadav; Donald F Kirby; Amandeep Singh
Journal:  Clin Rheumatol       Date:  2022-10-21       Impact factor: 3.650

3.  Clinical Characteristics of Systemic Sclerosis With Interstitial Lung Disease.

Authors:  Eunju Jung; Chang-Hee Suh; Hyoun-Ah Kim; Ju-Yang Jung
Journal:  Arch Rheumatol       Date:  2018-01-15       Impact factor: 1.472

4.  Clinical significance of self-reported cough intensity and frequency in patients with interstitial lung disease: a cross-sectional study.

Authors:  Ryuhei Sato; Tomohiro Handa; Hisako Matsumoto; Takeshi Kubo; Toyohiro Hirai
Journal:  BMC Pulm Med       Date:  2019-12-16       Impact factor: 3.317

5.  Antitussive Effect of a Chest Band in Patients with Interstitial Lung Disease: The Preliminary Results from a Pre-post Intervention Study.

Authors:  Ryuhei Sato; Tomohiro Handa; Hisako Matsumoto; Kota Hirai; Noriyuki Ohkura; Takeshi Kubo; Toyohiro Hirai
Journal:  Intern Med       Date:  2021-12-01       Impact factor: 1.271

6.  Research Burden of Interstitial Lung Diseases in Turkey - RBILD.

Authors:  Olcay Aycicek; Erdogan Cetinkaya; Fatma Demirci Ucsular; Nazan Bayram; Abdurrahman Senyigit; Nimet Aksel; Nurhan Atilla; Nurhan Sarıoglu; Elif Yelda Niksarlıoglu; Ahmet Ilgazlı; Talat Kılıc; Hulya Gunbatar; Sule Cilekar; Aydanur Ekici; Sibel Arınc; Hacı Ahmet Bircan; Dildar Duman; Ozlem Sengoren Dikis; Onur Yazıcı; Abdullah Kansu; Nuri Tutar; Emine Ozsarı; Serdar Berk; Yelda Varol; Ahmet Emin Erbaycu; Bunyamin Sertogullarından; Ali Kadri Cırak; Mustafa Cortuk; Gulistan Karadeniz; Alper Simsek; Cengizhan Sezgi C; Fuat Erel; Tuba Ciftci; Aysel Sunnetcioglu; Mehmet Savas Ekici; Ersin Gunay; Meltem Ağca; Onder Ozturk; Hamza Ogun; Elif Acar; Omer Tamer Dogan; Dursun Alizoroglu; Esma Gezer; Tevfik Ozlu
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-03-31       Impact factor: 0.670

7.  Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry.

Authors:  Wim A Wuyts; Caroline Dahlqvist; Hans Slabbynck; Marc Schlesser; Natacha Gusbin; Christophe Compere; Sofie Maddens; Shemra Rizzo; Klaus-Uwe Kirchgaessler; Karen Bartley; Benjamin Bondue
Journal:  Pulm Ther       Date:  2022-04-16

Review 8.  Cough in Idiopathic Pulmonary Fibrosis.

Authors:  Jennifer Mann; Nicole S L Goh; Anne E Holland; Yet Hong Khor
Journal:  Front Rehabil Sci       Date:  2021-10-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.